This is a multi-center, observational study of newly diagnosed IBD (CD or UC) patients. The Study aims to assess whether a prognostic biomarker can stratify IBD patients in the US.
Age
16–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Active UC or CD with typical symptoms in conjunction with at least one objective measure of disease activity: elevated CRP, calprotectin, endoscopic evidence.
Not currently receiving systemic therapy\* with steroids, immunomodulators or biologics, and at least 7 days since the last steroid dose.
Due to be managed using a "step-up" or "accelerated step-up" approach (so will not receive biologics as first line therapy).
Aged 16-80 years old.
Note, the ideal patients for this study are newly diagnosed patients who are treatment-naïve.
You may not be if
The presence of any of the following will preclude patient inclusion:
Patients with fistulating peri-anal Crohn's disease or active perianal sepsis.
Obstructive symptoms and evidence of a fixed stricture on radiology or colonoscopy.
Patients who are scheduled to start on "top-down" therapy or receive biologics as a first line therapy
